Evidence map›Paper›PMID 37063521›Full record

ArticleFrontiers in psychology2023

The assessment of executive functions to test the integrity of the nigrostriatal network: A pilot study.

Ciro Rosario Ilardi, Girolamo di Maio, Ines Villano, Giovanni Messina, Vincenzo Monda, Antonietta Messina, Chiara Porro, Maria Antonietta Panaro, Nadia Gamboz, Alessandro Iavarone and 1 more

Abstract read
In one paragraph

Article in Frontiers in psychology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ciro Rosario IlardiIRCCS Synlab SDN, Naples, Italy.
Girolamo di MaioDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Ines VillanoDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Giovanni MessinaDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Vincenzo MondaDepartment of Movement Sciences and Wellbeing, University of Naples "Parthenope", Naples, Italy.
Antonietta MessinaDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Chiara PorroDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Maria Antonietta PanaroDepartment of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy.
Nadia GambozLaboratory of Experimental Psychology, Suor Orsola Benincasa University, Naples, Italy.
Alessandro IavaroneNeurological Unit, CTO Hospital, AORN "Ospedali dei Colli", Naples, Italy.
Marco La MarraDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by motor and non-motor symptoms. The latter mainly include affective, sleep, and cognitive deficits. Non-demented PD patients often demonstrate impairments in several executive domains following neuropsychological evaluation. The current pilot study aims at assessing the discriminatory power of the Frontal Assessment Battery-15 (FAB15) in differentiating (i) non-demented PD patients and healthy controls and (ii) PD patients with more and less pronounced motor symptoms. Methods: Thirty-nine non-demented early-stage PD patients in the "on" dopamine state (26 females, mean age = 64.51 years, SD = 6.47, mean disease duration = 5.49 years, SD = 2.28) and 39 healthy participants (24 females, mean age = 62.60 years, SD = 5.51) were included in the study. All participants completed the FAB15. Motor symptoms of PD patients were quantified Results: The FAB15 score, adjusted according to normative data for sex, age, and education, proved to be sufficiently able to discriminate PD patients from healthy controls (AUC = 0.69 [95% CI 0.60-0.75], SE = 0.06, Conclusion: The FAB15 may be a valid tool for distinguishing PD patients from healthy controls. However, it might be less sensitive in identifying clinical phenotypes characterized by visuospatial impairments resulting from posteroparietal and/or temporal dysfunctions. In line with previous evidence, the battery demonstrated to be not expendable in the clinical practice for monitoring the severity of PD-related motor symptoms.

Indexed as

diagnosisexecutive functionsfrontal assessment battery-15motor symptomsParkinson’s disease

Identifiers

PMID37063521
PMCPMC10090354

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.